In vitro stability of arsenic trioxide-liposome encapsulates for acute promyelocytic leukemia treatment

Acute promyelocytic leukemia (APL) is characterized by the t(15;17) chromosomal translocation, leading to the formation of the promyelocytic leukemia-specific-retinoic acid receptor alpha (PML-RAR α or RARA) gene and is distinguished from other forms of PML by its responsiveness to all-trans retinoic acid (ATRA, also known as Tretinoin) therapy. It is a unique subtype of APL and accounts for about 10% of all acute myeloid leukemia (AML) cases in adults [1]. Promyelocytic leukemia was first d escribed in 1957 [2] as a fatal illness with a median survival time of less than a week.

Source: Leukemia Research - November 16, 2018 Category: Hematology Authors: Francisco Cunha da Rosa, Renan Buque Pardinho, Mauber Eduardo Schultz Moreira, Luiz Gustavo Teixeira de Souza, Érico Marlon de Moraes Flores, Sergio Roberto Mortari, Valderi Luiz Dressler Source Type: research